# R-RPLND as First-line Treatment for Clinical Stage IIA/B Testicular Seminoma

> **NCT05345158** · NA · RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 25 (estimated)

## Conditions studied

- Lymphadenopathy Retroperitoneal
- Stage II Testicular Seminoma

## Interventions

- **PROCEDURE:** Robotic Retroperitoneal Lymph Node Dissection (RPLND)

## Key facts

- **NCT ID:** NCT05345158
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-02-23
- **Primary completion:** 2030-11
- **Final completion:** 2030-11
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05345158

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05345158, "R-RPLND as First-line Treatment for Clinical Stage IIA/B Testicular Seminoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05345158. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*